Ann Intern Med. 2013;159;253-261Many patients with active RA have an inadequate response to biologic and nonbiologic DMARDs. Kremer et al carried out a one year, randomized trial studying the efficacy of tofacitinib in conjunction with background nonbiologic DMARDs (primarily methotrexate) in these patients. The results showed that using tofacitinib in combination with nonbiologic DMARDs rapidly improved physical function and reduced signs and symptoms of RA versus placebo, measured by ACR20 rates, DAS28 and HAQ-DI. The data found in this study is consistent with other studies carried out in tofacitinib in combination with methotrexate; however, due to the small sample sizes for the other DMARDs in this study, further tofacitinib studies need to be carried out in patients receiving nonmethotrexate DMARDs.